Royalty Pharma plc (RPRX): who owns it and who trades it
As of Nov 16, 2026, RPRX insiders reported 74 open-market sales worth $92.8M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Terrance P. Coyne (CFO), with $39M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Royalty Pharma
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RPRX
640 funds and institutions reported RPRX shares worth $20.7B at the end of Q2 2026. The largest holder is Morgan Stanley with $2.4B.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Morgan Stanley | 42.93M | – | $2.4B | -1% |
| Capital International Investors | 35.27M | – | $2B | +1% |
| BlackRock, Inc. | 27.83M | – | $1.6B | +7% |
| FMR LLC (Fidelity) | 24.51M | – | $1.4B | -3% |
| State Street Corp | 12.34M | – | $692M | +12% |
| T. Rowe Price Associates | 11.19M | – | $628M | +479% |
| Swedbank AB | 10.73M | – | $601M | -7% |
| Baillie Gifford & Co | 10.02M | – | $562M | -38% |
| Capital World Investors | 9.52M | – | $534M | +18% |
| Geode Capital Management, LLC | 8.06M | – | $451M | +2% |
| Caledonia (Private) Investments Pty Ltd | 5.78M | – | $324M | -19% |
| Norges Bank | 5.34M | – | $299M | – |
| Vanguard Capital Management LLC | 4.83M | – | $271M | +7% |
| Northern Trust Corp | 4.72M | – | $265M | +24% |
| Royal London Asset Management Ltd | 4.32M | – | $242M | +13% |
| AQR Capital Management LLC | 4.31M | – | $241M | +14% |
| Invesco Ltd. | 4.23M | – | $237M | +13% |
| Bank of America Corp | 4.15M | – | $233M | +19% |
| Legal & General Group Plc | 3.80M | – | $213M | +13% |
| Amundi | 3.72M | – | $209M | +21% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RPRX insiders reported $0 of open-market purchases and $92.8M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Marshall Urist | Vice president | Sale plan | 4,126 | $57.10 | $236K | Form 4 |
| Sep 28, 2026 | Marshall Urist | Vice president | Sale plan | 4,126 | $57.88 | $239K | Form 4 |
| Sep 22, 2026 | Christopher Hite | Vice president | Sale plan | 96,073 | $58.51 | $5.6M | Form 4 |
| Sep 22, 2026 | Christopher Hite | Vice president | Sale plan | 3,927 | $58.93 | $231K | Form 4 |
| Aug 18, 2026 | Christopher Hite | Vice president | Sale plan | 100,000 | $59.97 | $6M | Form 4 |
| Aug 13, 2026 | Terrance P. Coyne | CFO | Sale plan | 9,230 | $58.59 | $541K | Form 4 |
| Aug 13, 2026 | Terrance P. Coyne | CFO | Sale plan | 1,772 | $59.14 | $105K | Form 4 |
| Jul 1, 2026 | Marshall Urist | Vice president | Sale plan | 9,099 | $55.88 | $508K | Form 4 |
| Jun 30, 2026 | Christopher Hite | Vice president | Sale plan | 2,554 | $57.10 | $146K | Form 4 |
| Jun 30, 2026 | Christopher Hite | Vice president | Sale plan | 97,446 | $56.50 | $5.5M | Form 4 |
| Jun 30, 2026 | Christopher Hite | Vice president | Sale plan | 600 | $57.09 | $34.3K | Form 4 |
| Jun 30, 2026 | Christopher Hite | Vice president | Sale plan | 29,400 | $56.44 | $1.7M | Form 4 |
| Jun 24, 2026 | Marshall Urist | Vice president | Sale plan | 9,098 | $55.18 | $502K | Form 4 |
| Jun 23, 2026 | Christopher Hite | Vice president | Sale plan | 117,592 | $54.47 | $6.4M | Form 4 |
| Jun 23, 2026 | Christopher Hite | Vice president | Sale plan | 32,408 | $54.11 | $1.8M | Form 4 |
| May 26, 2026 | Terrance P. Coyne | CFO | Sale plan | 64,399 | $53.98 | $3.5M | Form 4 |
| May 20, 2026 | Marshall Urist | Vice president | Sale plan | 13,684 | $52.75 | $722K | Form 4 |
| May 14, 2026 | Marshall Urist | Vice president | Sale plan | 13,684 | $53.06 | $726K | Form 4 |
| May 14, 2026 | Gregory Norden | Director | Sale plan | 3,045 | $53.00 | $161K | Form 4 |
| Apr 28, 2026 | Terrance P. Coyne | CFO | Sale plan | 1,875 | $49.78 | $93.3K | Form 4 |
| Apr 28, 2026 | Terrance P. Coyne | CFO | Sale plan | 32,916 | $49.78 | $1.6M | Form 4 |
| Apr 1, 2026 | Terrance P. Coyne | CFO | Sale plan | 32,916 | $48.33 | $1.6M | Form 4 |
| Apr 1, 2026 | Terrance P. Coyne | CFO | Sale plan | 1,875 | $48.33 | $90.6K | Form 4 |
| Mar 23, 2026 | Terrance P. Coyne | CFO | Sale plan | 32,916 | $45.53 | $1.5M | Form 4 |
| Mar 23, 2026 | Terrance P. Coyne | CFO | Sale plan | 1,875 | $45.53 | $85.4K | Form 4 |
| Mar 2, 2026 | Terrance P. Coyne | CFO | Sale plan | 1,292 | $46.67 | $60.3K | Form 4 |
| Mar 2, 2026 | Terrance P. Coyne | CFO | Sale plan | 10,429 | $47.01 | $490K | Form 4 |
| Mar 2, 2026 | Terrance P. Coyne | CFO | Sale plan | 22,487 | $46.67 | $1M | Form 4 |
| Mar 2, 2026 | Terrance P. Coyne | CFO | Sale plan | 583 | $47.01 | $27.4K | Form 4 |
| Feb 23, 2026 | Terrance P. Coyne | CFO | Sale plan | 32,916 | $45.32 | $1.5M | Form 4 |
| Feb 23, 2026 | Terrance P. Coyne | CFO | Sale plan | 1,875 | $45.32 | $85K | Form 4 |
| Feb 4, 2026 | Terrance P. Coyne | CFO | Sale plan | 1,087 | $43.29 | $47.1K | Form 4 |
| Feb 4, 2026 | Terrance P. Coyne | CFO | Sale plan | 19,076 | $43.29 | $826K | Form 4 |
| Feb 3, 2026 | Terrance P. Coyne | CFO | Sale plan | 6,195 | $42.84 | $265K | Form 4 |
| Feb 3, 2026 | Terrance P. Coyne | CFO | Sale plan | 108,759 | $42.84 | $4.7M | Form 4 |
| Feb 2, 2026 | Terrance P. Coyne | CFO | Sale plan | 5,843 | $42.08 | $246K | Form 4 |
| Feb 2, 2026 | Terrance P. Coyne | CFO | Sale plan | 102,581 | $42.08 | $4.3M | Form 4 |
| Jan 30, 2026 | Marshall Urist | Vice president | Sale plan | 20,000 | $41.09 | $822K | Form 4 |
| Jan 23, 2026 | Marshall Urist | Vice president | Sale plan | 20,000 | $40.26 | $805K | Form 4 |
| Jan 20, 2026 | Terrance P. Coyne | CFO | Sale plan | 65,832 | $39.35 | $2.6M | Form 4 |
| Jan 20, 2026 | Terrance P. Coyne | CFO | Sale plan | 3,750 | $39.35 | $148K | Form 4 |
| Jan 16, 2026 | Marshall Urist | Vice president | Sale plan | 20,000 | $39.52 | $790K | Form 4 |
| Jan 9, 2026 | Marshall Urist | Vice president | Sale plan | 20,000 | $40.78 | $816K | Form 4 |
| Jan 2, 2026 | Terrance P. Coyne | CFO | Sale plan | 3,750 | $38.42 | $144K | Form 4 |
| Jan 2, 2026 | Terrance P. Coyne | CFO | Sale plan | 65,832 | $38.42 | $2.5M | Form 4 |
| Jan 2, 2026 | Marshall Urist | Vice president | Sale plan | 20,000 | $38.48 | $770K | Form 4 |
| Dec 26, 2025 | Marshall Urist | Vice president | Sale plan | 20,000 | $39.32 | $786K | Form 4 |
| Dec 19, 2025 | Marshall Urist | Vice president | Sale plan | 20,000 | $38.38 | $768K | Form 4 |
| Dec 18, 2025 | George W. Lloyd | Vice president | Sale plan | 30,654 | $38.50 | $1.2M | Form 4 |
| Dec 17, 2025 | George W. Lloyd | Vice president | Sale plan | 79,346 | $38.57 | $3.1M | Form 4 |
| Dec 16, 2025 | Marshall Urist | Vice president | Sale plan | 20,000 | $38.32 | $766K | Form 4 |
| Dec 15, 2025 | Terrance P. Coyne | CFO | Sale plan | 3,750 | $38.36 | $144K | Form 4 |
| Dec 15, 2025 | Terrance P. Coyne | CFO | Sale plan | 65,832 | $38.36 | $2.5M | Form 4 |
| Dec 5, 2025 | Marshall Urist | Vice president | Sale plan | 23,334 | $39.15 | $914K | Form 4 |
| Dec 5, 2025 | Marshall Urist | Vice president | Sale plan | 18,242 | $39.15 | $714K | Form 4 |
| Dec 3, 2025 | George W. Lloyd | Vice president | Sale plan | 110,000 | $39.77 | $4.4M | Form 4 |
| Dec 1, 2025 | Terrance P. Coyne | CFO | Sale plan | 3,750 | $39.87 | $150K | Form 4 |
| Dec 1, 2025 | Terrance P. Coyne | CFO | Sale plan | 65,832 | $39.87 | $2.6M | Form 4 |
| Dec 1, 2025 | Marshall Urist | Vice president | Sale plan | 18,242 | $39.90 | $728K | Form 4 |
| Dec 1, 2025 | Marshall Urist | Vice president | Sale plan | 23,333 | $39.93 | $932K | Form 4 |
| Nov 24, 2025 | Terrance P. Coyne | CFO | Sale plan | 55,146 | $38.67 | $2.1M | Form 4 |
| Nov 24, 2025 | Terrance P. Coyne | CFO | Sale plan | 624 | $37.96 | $23.7K | Form 4 |
| Nov 24, 2025 | Terrance P. Coyne | CFO | Sale plan | 3,126 | $38.67 | $121K | Form 4 |
| Nov 24, 2025 | Terrance P. Coyne | CFO | Sale plan | 10,686 | $37.96 | $406K | Form 4 |
| Nov 19, 2025 | George W. Lloyd | Vice president | Sale plan | 4,599 | $39.01 | $179K | Form 4 |
| Nov 19, 2025 | George W. Lloyd | Vice president | Sale plan | 230 | $39.03 | $9K | Form 4 |
| Nov 19, 2025 | George W. Lloyd | Vice president | Sale plan | 47,798 | $38.28 | $1.8M | Form 4 |
| Nov 19, 2025 | George W. Lloyd | Vice president | Sale plan | 4,628 | $39.01 | $181K | Form 4 |
| Nov 19, 2025 | George W. Lloyd | Vice president | Sale plan | 47,401 | $38.28 | $1.8M | Form 4 |
| Nov 19, 2025 | George W. Lloyd | Vice president | Sale plan | 25,530 | $38.28 | $977K | Form 4 |
| Nov 19, 2025 | George W. Lloyd | Vice president | Sale plan | 2,470 | $39.01 | $96.4K | Form 4 |
| Nov 19, 2025 | George W. Lloyd | Vice president | Sale plan | 2,770 | $38.29 | $106K | Form 4 |
| Nov 17, 2025 | Terrance P. Coyne | CFO | Sale plan | 65,844 | $39.30 | $2.6M | Form 4 |
| Nov 17, 2025 | Terrance P. Coyne | CFO | Sale plan | 3,750 | $39.30 | $147K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Terrance P. Coyne | EVP & CFO | – | $39M | Aug 13, 2026 |
| Christopher Hite | EVP & Chairman, Partnering | – | $27.4M | Sep 22, 2026 |
| George W. Lloyd | EVP, Investments & CLO | – | $13.8M | Dec 18, 2025 |
| Marshall Urist | EVP, Research & Investments | – | $12.5M | Oct 5, 2026 |
| Gregory Norden | Director | – | $161K | May 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RPRX short interest
13.08M RPRX shares are sold short. Over the last 12 reports the number of shares short went up 3%.
As of Oct 30, 2026, 13.08M RPRX shares were sold short, up 1.8% from the report before. At the average daily volume of 3.30M shares, buying them all back would take about 4.0 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 13.08M | – | +2% | 3.30M | 4.0 |
| Oct 15, 2026 | 12.84M | – | -0% | 3.00M | 4.3 |
| Sep 30, 2026 | 12.89M | – | +11% | 2.90M | 4.4 |
| Sep 15, 2026 | 11.65M | – | -2% | 3.59M | 3.2 |
| Aug 31, 2026 | 11.90M | – | +3% | 2.36M | 5.0 |
| Aug 14, 2026 | 11.61M | – | +9% | 3.08M | 3.8 |
| Jul 31, 2026 | 10.67M | – | -12% | 2.62M | 4.1 |
| Jul 15, 2026 | 12.13M | – | -2% | 2.73M | 4.4 |
| Jun 30, 2026 | 12.44M | – | +12% | 4.18M | 3.0 |
| Jun 15, 2026 | 11.13M | – | -4% | 3.67M | 3.0 |
| May 29, 2026 | 11.59M | – | -9% | 4.69M | 2.5 |
| May 15, 2026 | 12.68M | – | -8% | 3.82M | 3.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Royalty Pharma company events
Royalty Pharma filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 28, 2026AgreementRoyalty Pharma plc, Royalty Pharma Holdings Ltd, a non-wholly owned consolidated subsidiary of the Company, and Royalty Pharma Manager, LLC entered into that certain Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent and the other lenders thereto. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 13, 2026AnnouncementShared information with investors. Filing
- Feb 11, 2026ResultsReleased financial results. Filing
- Dec 22, 2025LeadershipGeorge W. Lloyd, age 66, informed Royalty Pharma plc of his decision to transition from his role of Executive Vice President and Chief Legal Officer effective December 31, 2025. Filing
- Dec 22, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Royalty Pharma financials
Famous investors that hold RPRX
6 of the 50 well-known investors we track reported holding RPRX in their latest 13F filing. The largest position is Ken Griffin's, worth $85.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.47M | $85.9M | 0.0% | +9% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.12M | $65.6M | 0.1% | +954% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 591,100 | $34.5M | 0.0% | -69% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 510,736 | $29.8M | 0.1% | -16% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 474,521 | $27.7M | 0.1% | +116% |
| Israel Englander · Millennium Management | Q3 2026 | 65,043 | $3.8M | 0.0% | +440% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RPRX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 4.3% |
| Nov 5, 2026 | FMR LLC | 13G/A | 4.3% |
Questions about Royalty Pharma plc (RPRX) stock
Who owns the most RPRX stock?
The largest reported owner of Royalty Pharma plc (RPRX) is Morgan Stanley. In total, 640 funds and institutions reported holding RPRX at the end of Q2 2026. See the largest owners.
Are RPRX insiders buying or selling?
In the last 12 months, RPRX insiders reported no open-market purchases and 74 sales worth $92.8M. The latest trade was on Oct 5, 2026. See every trade.
What is the short interest in RPRX?
As of Oct 30, 2026, 13.08M RPRX shares were sold short, up 1.8% from the report before. At the average daily volume of 3.30M shares, buying them all back would take about 4.0 trading days (days to cover). See the history.
Which famous investors hold RPRX?
6 of the 50 well-known investors we track reported RPRX in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $85.9M. See all holders.
Executive pay
Royalty Pharma's chief executive was paid a total of $938K for the year ended Dec 31, 2025. In the last 12 months, Royalty Pharma's executives and directors bought no stock on the open market and sold $92.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.